I am not underwriting a dramatic software-style
rerating. The upside comes from higher utilization, more direct workflow control, better recurring healthcare mix, and a trust layer around verified task completion. If Serve clears those gates, investors can value it as a credible physical-AI operator with recurring workflow revenue rather than a subsidized pilot fleet. If it stays a thin subcontractor behind larger platforms, the
rerating stalls.